2.36
-0.04(-1.67%)
Currency In USD
Address
7801 North Capital of Texas Highway
Austin, TX 78731
United States of America
Phone
512 501 2444
Sector
Healthcare
Industry
Biotechnology
Employees
29
First IPO Date
July 14, 2000
| Name | Title | Pay | Year Born |
| Mr. Richard Jon Barry | Chief Executive Officer, President & Director | 7,500 | 1959 |
| Mr. R. Christopher Cook J.D. | Senior Vice President, Company Secretary & General Counsel | 425,000 | 1964 |
| Dr. James W. Kupiec M.D. | Chief Medical Officer | 435,000 | 1953 |
| Mr. Eric J. Schoen | Chief Financial Officer | 460,000 | 1968 |
| Mr. Michael Zamloot | Senior Vice President of Technical Operations | 0 | N/A |
| Jaren Landen | Chief Clinical Development Officer | 0 | N/A |
| Ms. Freda Nassif | Chief Commercial Officer | 0 | N/A |
| Dr. George Thornton Ph.D. | Senior Vice President of Technology | 0 | N/A |
| Dr. Michael Marsman Pharm.D. | Senior Vice President of Regulatory Affairs | 0 | N/A |
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.